Tag: Boehringer Ingelheim

7 Potential Blockbuster Drugs Investors Should Watch for in 2019

A report by Cortellis says that seven drugs entering the market in 2019 are projected to reach blockbuster status by...

Boehringer Ingelheim Partners with Epizyme

Boehringer Ingelheim and Epizyme announced a partnership on Thursday to develop oncology treatments.The partnership entails developing, researching and commercializing small...

Boehringer Ingelheim and Eli Lilly Share Positive Phase 3 Results

Empaglifozin was used in those trials in combination with traditional insulin therapy to evaluate if it could provide blood sugar...

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced that both randomised controlled trials in the EASE phase III...